(CLSD) Clearside Biomedical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1850631045

CLSD: Eye, Injection, Suspension, Treatment, Uveitis, AMD

Clearside Biomedical, Inc. (NASDAQ:CLSD) is a biopharmaceutical company pioneering the delivery of therapies to the back of the eye via the suprachoroidal space, a novel approach designed to enhance drug distribution and efficacy for ocular diseases. The companys lead product, XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), is approved for the treatment of macular edema associated with uveitis, a condition causing inflammation and vision impairment. Additionally, Clearside is advancing CLS-AX (axitinib injectable suspension) through a Phase IIb clinical trial for the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The company has established strategic collaborations with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences to expand its pipeline and capabilities. Incorporated in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical focuses on addressing significant unmet needs in ophthalmology.

As of the latest data, Clearside Biomedical, Inc. (NASDAQ:CLSD) has a market capitalization of $78.12 million, with a price-to-book (P/B) ratio of 3.93 and a price-to-sales (P/S) ratio of 10.14. The companys return on equity (RoE) stands at 91.63%. On the technical side, the stock is trading at $0.85, below its 20-day simple moving average (SMA) of $0.98 and 50-day SMA of $0.95, while its 200-day SMA is at $1.11. The average true range (ATR) is 0.06, indicating relatively low volatility. The stocks average 20-day volume is 266,788 shares.

3-Month Forecast: Based on and , CLSD is expected to remain under pressure in the near term, as the stock is trading below its key moving averages. However, the low ATR and proximity to 52-week lows may attract value-oriented investors. Fundamental analysis suggests the companys high P/S ratio could indicate overvaluation unless supported by positive clinical trial outcomes or collaboration milestones. The stocks trajectory will likely depend on updates from the CLS-AX Phase IIb trial and potential catalysts from its partnerships. Investors should monitor both technical support levels and fundamental developments for clarity on the stocks direction.

Additional Sources for CLSD Stock

CLSD Stock Overview

Market Cap in USD 65m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2016-06-02

CLSD Stock Ratings

Growth 5y -58.5%
Fundamental -4.39%
Dividend 0.0%
Rel. Strength Industry -49
Analysts 4.57/5
Fair Price Momentum 0.67 USD
Fair Price DCF -

CLSD Dividends

No Dividends Paid

CLSD Growth Ratios

Growth Correlation 3m -32.8%
Growth Correlation 12m -81.5%
Growth Correlation 5y -75.7%
CAGR 5y -9.66%
CAGR/Max DD 5y -0.11
Sharpe Ratio 12m -2.68
Alpha -60.74
Beta 1.23
Volatility 82.84%
Current Volume 75.4k
Average Volume 20d 204.5k
What is the price of CLSD stocks?
As of March 15, 2025, the stock is trading at USD 0.89 with a total of 75,448 shares traded.
Over the past week, the price has changed by -4.11%, over one month by -16.85%, over three months by -11.91% and over the past year by -48.57%.
Is Clearside Biomedical a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Clearside Biomedical is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -4.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLSD as of March 2025 is 0.67. This means that CLSD is currently overvalued and has a potential downside of -24.72%.
Is CLSD a buy, sell or hold?
Clearside Biomedical has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy CLSD.
  • Strong Buy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CLSD stock price target?
According to ValueRays Forecast Model, CLSD Clearside Biomedical will be worth about 0.8 in March 2026. The stock is currently trading at 0.89. This means that the stock has a potential downside of -13.48%.
Issuer Forecast Upside
Wallstreet Target Price 6 574.2%
Analysts Target Price 6 574.2%
ValueRay Target Price 0.8 -13.5%